Ausgabe 10/ 2009, S. 34
Zurück zum Inhaltsverzeichnis
Fortbildung CME Neurologie

Morbus Parkinson

Können wir die Erkrankung aufhalten?

Carsten Buhmann, Hamburg

Die Therapie des Morbus Parkinson basiert auf der Subs titution des krankheitsbedingten chronisch progredienten dopaminergen Defizits, entweder durch Substitution von Dopamin in Form von Levodopa, durch Erhöhung des dopaminergen Angebots im Gehirn durch die Gabe von den Dopaminabbau hemmenden Substanzen (MAO-B- oder COMT- Hemmer) oder durch die direkte Stimulation von Dopaminrezeptoren durch Dopaminagonisten. Die dopaminerge Therapie ist besonders in den ersten Jahren der Erkrankung effektiv [1, 2], allerdings ist die chronische Levodopabehandlung mit der Entwicklung von motorischen Spätkomplikationen assoziiert.

CME-Fragen bei www.CME-Punkt.de

Korrespondenzadresse
PD Dr. med. Carsten Buhmann
Ambulanzzentrum – Bereich Neurologie und Klinik für Neurologie, Universitätsklinikum Hamburg-Eppendorf,
Martinistraße 52
D-20246 Hamburg
Tel.: 040/7410-52771, Fax: 040/7410-45780

Literatur

  1. Olanow CW, Watts RL, Koller WC: An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 56:1-88, 2001
  2. Rascol O, Goetz C, Koller W et al.: Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 359:1589-1598, 2002
  3. Braak H, Del Tredici K, Rub U et al.: Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211, 2003
  4. Lang AE, Obeso JA: Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Ann Neurol 55:761-765, 2004
  5. Schapira AH, Olanow CW: Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA 291:358-364, 2004
  6. Schapira AH: Science, medicine, and the future: Parkinson's disease. BMJ 318:311-314, 1999
  7. Schapira AH: Disease modification in Parkinson's disease. Lancet Neurol 3:362-368, 2004
  8. Schapira AH, Obeso J: Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 59:559-562, 2006
  9. Grosset D, Taurah L, Burn DJ et al.: A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 78:465-469, 2007
  10. Hornykiewicz O, Kish SJ: Biochemical pathophysiology of Parkinson's disease. Adv Neurol 45:19-34, 1987
  11. Riederer P, Wuketich S: Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 38:277-301, 1976
  12. Tissingh G, Bergmans P, Booij J et al.: Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT. J Neurol 245:14-20, 1998
  13. Tissingh G, Booij J, Bergmans P et al.: Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med 39:1143-1148, 1998
  14. Goetz CG, Poewe W, Rascol O, Sampaio C: Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 20:523-539, 2005
  15. Stewart DA: NICE guideline for Parkinson's disease. Age Ageing 36:240-242, 2007
  16. Horstink M, Tolosa E, Bonuccelli U et al.: Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol 13:1170-1185, 2006
  17. Suchowersky O, Gronseth G, Perlmutter J et al.: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:976-982, 2006
  18. Hung AY, Schwarzschild MA: Clinical trials for neuroprotection in Parkinson's disease: overcoming angst and futility? Curr Opin Neurol 20:477-483, 2007
  19. Leber P: Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord 11 Suppl 5:S10-S21, 1997
  20. Leber P: Observations and suggestions on antidementia drug development. Alzheimer Dis Assoc Disord 10 Suppl 1:31-35, 1996
  21. Parkinson Study Group: DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol 46:1052-1060, 1989
  22. Fahn S, Oakes D, Shoulson I et al.: Levodopa and the progression of Parkinson's disease. N Engl J Med 351:2498-2508, 2004
  23. Parkinson Study Group: A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61:561-566, 2004
  24. Palhagen S, Heinonen E, Hagglund J et al.: Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66:1200-1206, 2006
  25. Parkinson Study Group: Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA 284:1931-1938, 2000
  26. Rakshi JS, Pavese N, Uema T et al.: A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. J Neural Transm 109:1433-1443, 2002
  27. Parkinson Study Group: A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 59:1937-1943, 2002
  28. Hauser RA, Lew MF, Hurtig HI et al.: Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord 24:564-573, 2009
  29. Olanow CW, Hauser RA, Jankovic J et al.: A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 23:2194-2201, 2008
  30. Olanow CW, Rascol O. works in progress abstracts. Ann. Neurol.[64 (suppl 12)], 68. 2008.
  31. Freed CR, Greene PE, Breeze RE et al.: Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344:710-719, 2001
  32. Olanow CW, Goetz CG, Kordower JH et al.: A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54:403-414, 2003
  33. Piccini P, Brooks DJ, Bjorklund A et al.: Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci 2:1137-1140, 1999
  34. Lindvall O, Hagell P: Role of cell therapy in Parkinson disease. Neurosurg Focus 13:e2, 2002
  35. Breysse N, Carlsson T, Winkler C et al.: The functional impact of the intrastriatal dopamine neuron grafts in parkinsonian rats is reduced with advancing disease. J Neurosci 27:5849-5856, 2007
  36. Piccini P, Pavese N, Hagell P et al.: Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 128:2977-2986, 2005
  37. Carlsson T, Winkler C, Lundblad M et al.: Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol Dis 21:657-668, 2006
  38. Stover NP, Watts RL: Spheramine for treatment of Parkinson's disease. Neurotherapeutics 5:252-259, 2008
  39. Kaplitt MG, Feigin A, Tang C et al.: Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369:2097-2105, 2007
  40. Marks WJ, Jr., Ostrem JL, Verhagen L et al.: Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 7:400-408, 2008
  41. Eberling JL, Jagust WJ, Christine CW et al.: Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70:1980-1983, 2008